Chris Ryan

Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.

Ivonescimab monotherapy improved PFS vs pembrolizumab in the first-line treatment of PD-L1–positive NSCLC in China.

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma.

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

Tumor-infiltrating B lymphocytes were associated with worse outcomes in patients with metastatic ccRCC treated with axitinib plus anti–PD-1 therapy.

The FDA has granted orphan drug designation to azeliragon as a potential therapeutic option for patients with pancreatic cancer.

The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.

The FDA has withdrawn the approval of infigratinib for previously treated, FGFR2-positive, advanced cholangiocarcinoma.

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer.

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.

The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.

The FDA has granted orphan drug designation to 9MW2821 as a potential treatment for patients with esophageal cancer.

Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.

The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of developing colorectal cancer.

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.